---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123303"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:18:57.477980+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q3 cash $57.7M; initial CRDF-004 data expected by year-end

## Summary
- Cash, equivalents, and short-term investments of $57.7M as of Sept 30, 2024.
- Net cash used in operations: $10.5M in Q3 2024, up from $8.0M in Q3 2023.
- Total operating expenses $12.8M for Q3 2024, an increase of $1.8M YoY.
- Initial data readout from first-line RAS-mutated mCRC CRDF-004 trial expected by end of 2024.
- Phase 2 trial in second-line KRAS-mutant mCRC published in Journal of Clinical Oncology; bev naïve patients had ORR 77% and mPFS 14.9 months.

## SEC filing metadata
- accession: 0000950170-24-123303
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000095017024123303/0000950170-24-123303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000095017024123303/crdf-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123303
- JSON: https://secwatch.observer/filing/0000950170-24-123303.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.